The healthcare industry is experiencing a real revolution with the rise of biotherapies. This market of nearly 200 billion euros (24.3% of the global drug market in 2019) is expected to grow between 8% and 9% per year to reach 320 billion euros by 2025. These new therapies represent a major economic challenge, as well as a future challenge for our healthcare system and our health sovereignty. The Grand Est Region has undeniable assets to become a key partner in bioproduction. Indeed, the Grand Est region is the only one to combine the presence and strong expertise in bioproduction and bioeconomy. The bioproduction project, modelled on Act 2 of the Grand Est Business Act jointly desired by the Grand Est Region and the State - aims to implement a transformation path through specific expertise in health, industry 5.0, digital and ecology. The proposed work consists in understanding the production cycle of new biomedicines in a global way, from the design of equipment/consumables, ideally eco-designed, more efficient, to the production of biotherapies accessible to patients, in order to ensure a sustainable production cycle allowing a controlled management of the rise of the bioproduction market.